Liquidia (NASDAQ:LQDA) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Liquidia (NASDAQ:LQDA) announced its earnings results on Monday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03), Zacks reports. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%.

Liquidia Stock Performance

Shares of LQDA opened at $15.32 on Monday. The company has a 50 day moving average price of $14.25 and a 200-day moving average price of $13.18. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.81. The stock has a market capitalization of $1.31 billion, a PE ratio of -9.40 and a beta of 0.24.

Analysts Set New Price Targets

Several brokerages recently commented on LQDA. Raymond James upped their price target on shares of Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday, March 20th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Liquidia in a report on Thursday, April 10th. Finally, Scotiabank reiterated an “outperform” rating on shares of Liquidia in a report on Monday, May 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Liquidia presently has an average rating of “Buy” and an average price target of $27.13.

Insider Transactions at Liquidia

In related news, insider Jason Adair sold 1,856 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the sale, the insider now owns 184,304 shares of the company’s stock, valued at $2,501,005.28. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Rajeev Saggar sold 2,450 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the sale, the insider now directly owns 263,152 shares of the company’s stock, valued at $3,597,287.84. The trade was a 0.92% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,138 shares of company stock valued at $450,233. Company insiders own 26.50% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).